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Antibodies to glutamic acid decarboxylase (GAD-Ab) are considered to be markers of autoimmune type 1 diabetes mellitus because they are found in the serum of most type 1 diabetes patients even before clinical onset. 1 GAD-Ab are also found in possibly immune-mediated syndromes affecting the central nervous system (CNS), including stiff-person syndrome 2 and a small group of patients with cerebellar ataxia. [3] [4] The role of GAD-Ab in the pathogenesis of these neurological disorders is not known. Some authors argue that GAD-Ab might simply reflect the frequent association of these diseases with diabetes mellitus. There is evidence to the contrary, however: 1.some patients never develop diabetes, 2.the GAD epitopes recognized by sera from neurological patients are different from those recognized by sera from patients with diabetes mellitus alone. 3 , 3.GAD-Ab titers are significantly higher in the serum of neurological patients. Intrathecal synthesis has been demonstrated in a few patients with neurological involvement, suggesting a possible pathogenic role of GAD-Ab in neurological symptoms. 3, 5 In vitro, GAD-Ab from patients with neurological syndromes induce a suppression of gammaamino-butyric acid (GABA) release. [6] [7] In a whole-cell patch-clamp model with rat cerebellar slices, GAD-Ab were shown to modulate inhibitory potentials in interneurons in a dosedependent manner and to down-regulate GABA synthesis in basket cells terminals, reducing GABA release on post-synaptic Purkinje cells. 6 GAD-Ab may therefore impair neuronal activity and interfere with the regulation of brain neurotransmitters. However, the effects of GAD-Ab have not been studied in the intact animal thus far. We assessed the in vivo effects of GAD-Ab extracted from patients with or without neurological symptoms on: (1) the adaptation of the motor cortex to sustained peripheral stimulation, a model of learning requiring the integrity of the cerebellum, [8] [9] (2) the spontaneous motor activity in skeletal muscle, the exteroceptive reflexes and the F/M ratios, 10 (3) the NMDA-induced production of nitric oxide (NO) in the cerebellum, 11 (4) the regulation of extra-cellular concentrations of glutamate following administration of NMDA in deep cerebellar nuclei.
Methods
Antibodies. Sera were collected from five patients with GAD-Ab and neurological syndromes (three with stiff-person syndrome and two with cerebellar ataxia). None of them had diabetes mellitus. Control sera were obtained from three patients with paraneoplastic cerebellar ataxia (one anti-Hu-positive; one anti-Yo-positive; one anti-CV2/CRMP5-positive), and from three patients with diabetes mellitus and GAD-Ab, but no neurological signs. All sera were stored at -80°C before the experiments. All experiments were performed with a purified IgG fraction. IgG were adsorbed to protein ASepharose beads (proteinA Sepharose 4 fast flow, Amersham Biosciences, France) and eluted with sodium citrate (0.5M, pH 2.5). After neutralization, samples were dialyzed overnight at 4°C against Ringer solution (Frenesius Kabi, France) and sterilized by filtration with 0.22 µm filters. Protein concentration was measured by the Bradford method (Bio-Rad protein assay, Bio-Rad, France) and each sample was diluted or concentrated to obtain a protein level of 1 mg/ml. The control solution was prepared with citrate buffer (0.5M, pH 2.5) neutralized and dialysed against Ringer solution in order to avoid osmotic drifts. Animal studies were approved by the institutional animal care committee of the Free University of Brussels. Experiments were conducted in male Wistar rats (Charles River Laboratories; weight between 250 and 300 g). See also table 1 for a summary of the experiments carried out. Microdialysis procedure. The day before the neurochemical investigations, animals were anesthetized for surgery using a loading dose of chloral hydrate given ip (400 mg/kg). The skull was exposed and an intra-cerebellar guide was implanted (coordinates of the extremity of the guide were AP: -11.6, L: +2.3, V: -4.6; all coordinates are related to bregma according to the atlas of Paxinos and Watson). The guide was fixed with dental cement and a probe was immediately inserted through the guide. A CMA/10 probe (length: 2 mm, diameter: 0.5 mm) was inserted in the left cerebellum using a stereotactic frame (accuracy < 0.1 mm). The probe was connected to a microinfusion pump and perfused with Ringer solution at a flow rate of 2 microL/min. The rats were allowed to recover and were given free access to water and food. Twenty-four hours later, another loading dose of chloral hydrate (400 mg/kg ip) was administered, followed by continuous ip infusion at a rate of 2 microL/min. A volume of 5 microL of solution (control solution or solution with Ab) was injected over a period of 5 minutes through the guide. The probe was then reinserted in the guide (CMA12, Carnegie Medicin, Sweden) and continuously perfused with a Ringer's solution (containing 148 mM NaCl, 1.1 mM CaCl2 and 4mM KCl, pH +/-7.2.) at a flow rate of 2 microL/min. All the animals underwent cerebellar surgery on the left side. At the end of the experiments, an overdose of chloral hydrate was administered and the brain was removed from the skull for histological verification of the location of the probe.
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Modulation of motor cortex excitability. We investigated the evoked responses in the left gastrocnemius muscle following stimulation of the right motor cortex, before (basal condition) and after repetitive electrical stimulation of the left sciatic nerve. 8, 12 Chloral hydrate was administered continuously at 2 microL/min (CMA100 micropump; CMA, Sweden) using the ip route. 9 Anesthesia depth was adjusted for absence of abdominal contractions in response to tail pinch. The left sciatic nerve was surgically exposed for bipolar stimulation. Duration of stimulation was one hour. Trains of stimulation were delivered at a rate of 10 Hz (a train being composed of 5 stimuli of a 1 msec duration; A310-A365 stimulator -World Precision Instruments, UK). Stimulus intensity was adjusted to produce constant somatosensory evoked potentials (SEP) in the EEG. 12 We specifically investigated the modulation of motor cortex excitability before and 1 hour after intra-cerebellar microinjection (see also the microdialysis procedure). For the stimulation of the right motor cortex, square stimuli were applied via screws fixed on the skull at the level of the motor cortex. 8 Peak-to-peak amplitudes in motor responses of the left gastrocnemius muscle were studied. Motor threshold was defined as the lowest intensity eliciting at least 5 out of 10 evoked responses with an amplitude > 20 microVolts. The sigmoid feature of the recruitment curve was checked in each rat. 12 The intensity of stimulation was 130% of motor threshold. 9 Filter settings were 30 Hz-1.5 KHz (NeuroMax 4, Xltek, Canada). NO measurement. To assess NMDA-induced production of NO, experiments were conducted: (1) in a control group of rats (Group I: n = 6) injected in the cerebellum with a control solution, (2) in a group of rats (Group II, n= 8) injected in the cerebellum with IgG from patients with GAD-Ab and neurological symptoms, (3) in a second control group of rats injected in the cerebellum with IgG from patients with paraneoplastic cerebellar ataxia (anti-Yo Ab n = 6; antiHu Ab n = 6; anti-CV2 Ab n = 6). We assessed also the effects of NMDA on the extra-cellular concentration of glutamate in six control rats and in five rats injected with IgG from GAD-Ab positive patients with neurological symptoms. Three baseline measurements of NO were performed in each rat to assess the variability in the basal condition.
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NMDA (concentration: 10 mM) was administered in the probe and microdialysates were collected every 20 minutes (volume of each sample: 40 microL). NO concentrations were measured using a Nitric Oxide Quantitation Kit (Active Motif, Belgium) with a two-step assay method involving the addition of two cofactors to the nitrate reductase reaction. The reductase reaction was completed within 30 minutes and colorimetric determinations were directly measured by the addition of Griess Reagent, which converts nitrite into a purple-colored azo compound. Standard curves for both nitrate and nitrite were verified for each experiment. The absorbance was read on a spectrophotometer at 540 nm with a reference wavelength of 620 nm. The validation of the 5 method (stability of baseline measurements, as well as use of inhibitors of NO synthase such as L-NAME) has been published previously.
Glutamate measurement. After stabilisation of baseline measurements, samples were collected every 20 minutes to measure extra-cellular concentrations of glutamate. We used the CMA/600 device (Aurora Borealis Control; glutamate oxidase method) for the quantitative determination of glutamate in microdialysates. Spontaneous muscle activity. We investigated the spontaneous muscle activity in the left gastrocnemius muscle (5 recording sites) before (30 minutes) and after (45 minutes) the paraspinal administration of antibodies at the lumbar level. The spinal cord was surgically exposed using a microscope and a micro-injection of 10 microL (injected over a period of 10 minutes) was performed. A micromanipulator was used for the EMG study as reported previously. 13 The spinal cord was subsequently dissected to check for the absence of local bleeding. In addition, both motor cortex stimulation and somatosensory evoked potentials (SEP) were used to monitor the absence of damage to the long tracts following the injection of antibodies. F-waves and M response. The F-waves and the direct motor responses (M response) were studied according to a method adapted from Gozariu et al. 14 Electrical stimulation of the left tibial nerve was achieved through a pair of needle electrodes inserted subcutaneously at the ankle, behind the medial malleolus. Electrical stimuli consisted of single square-wave shocks of 0.5 msec duration, delivered every 6 seconds. EMG recordings were obtained from the ispilateral plantaris muscle through a pair of needle electrodes inserted in the distal third of the sole (filters 30 Hz-1.5 KHz). We assessed the ratio mean F/mean M wave amplitudes following 50 supramaximal stimuli. [8] [9] These studies were first performed in the basal condition. As expected, Mean F/Mean M responses were similar in the 4 groups of rats investigated in the basal condition prior administration of antibodies (group 1 -controls: no administration of fluid; group 2: rats receiving saline administration; group 3: rats receiving IgG from patients with GAD-Ab and stiff-person syndrome or cerebellar ataxia; group 4: administration of GAD-Ab from patients without neurological symptoms). Mean values were in the range of 9 to 13 %. 8 We analysed these ratios 1 hour after administration of antibodies. Exteroceptive reflexes were assessed by analysing the response of ipsilateral lower limbs following electrical stimulation of the sole with rectangular electrical stimuli (duration of pulses: 0.3 msec; intensity: 1 to 3 mA). Subcutaneous needles were inserted proximally at the level of left gastrocnemius muscle and distally at the level of the left plantaris muscle.
Statistical analysis
The effects of repetitive peripheral stimulation on the amplitude of motor evoked potentials were evaluated in each of the 4 groups of rats (controls, administration of Ringer, administration of GAD-Ab from patients with neurological symptoms, administration of GAD-Ab from patients with diabetes in absence of neurological symptoms) using the Student t test. The mean F/mean M response ratio was compared among the 4 groups using the analysis of variance (ANOVA). The effects of antibodies on NMDA-induced production of NO and on regulation of glutamate concentrations by NMDA were evaluated by ANOVA, followed by multiple comparisons procedure. 15 
Results

Potentiation of the corticomotor response
We investigated the evoked responses in the left gastrocnemius muscle following stimulation of the right motor cortex before (basal condition) and after repetitive electrical stimulation of the left sciatic nerve. Figure 1A shows the corticomotor responses in a control rat (no intracerebellar administration), in an animal injected with Ringer solution, in an animal injected with 6 IgG from patients with GAD-Ab and neurological symptoms, and in a rat injected with IgG from patients with GAD-Ab and diabetes mellitus but no neurological signs. The enhancement of the corticomotor response is blocked when IgG from patients with GAD-Ab and neurological symptoms are injected. Baseline motor responses (before concurrent somatosensory stimulation) showed similar peak-to-peak values in the 4 groups ( Figure 1B ). In rats with no cerebellar injection, in rats with Ringer infusion and in rats injected with IgG from patients with diabetes mellitus, the cortico-muscular response was enhanced after repetitive stimulation of the sciatic nerve (stimulation effect: p < 0.01 in each group). By contrast, there was no enhancement of the peak-to-peak response when IgG from patients with GAD-Ab and neurological syndromes were administered into the cerebellar nuclei (p = 0.18). Thus, potentiation was specifically impaired when rats were injected with IgG extracted from patients exhibiting neurological signs and GAD-Ab.
Skeletal muscle/spinal cord function
We investigated the spontaneous muscle activity in the left gastronemius muscle, before and after administration of IgG at the paraspinal lumbar level. As shown in figure 2, IgG from patients with GAD-Ab and neurological symptoms induced continuous motor activity in the gastrocnemius muscle, with repetitive discharges. Spontaneous small muscle twitches in lower limbs were observed in 5 of the 6 rats injected with GAD-Ab from neurological patients. However, no visible distortion of the spine was induced. Exteroceptive reflexes became abnormal with exaggerated proximal and distal responses of the ipsilateral limbs following electrical stimulation of the skin without evidence of long tract disturbance. In all the rats injected with IgG from neurological patients with GAD-Ab, stimulation of the sole resulted in visible contractions of the gastrocnemius muscle with bursts having a latency of 7-12 msec. This exaggerated response was absent in the other groups with no bursts of muscle activity in the left gastrocnemius muscle. F/M ratios increased one hour after IgG administration when antibodies from patients with neurological signs and GAD-Ab were used (Figure 3) . IgG from patients with stiff-person syndrome and with cerebellar ataxia were equally effective. Again, no effect was found with IgG extracted from patients without neurological symptoms (analysis of variance, inter-group effect p < 0.01).
NO and glutamate concentration
We tested in vivo by microdialysis how GAD-Ab affected the glutamate/NO pathway in the cerebellum ( Figure 4 ). As expected, in the control group administration of NMDA was associated with a significant increase in NO levels (p = 0.002). In rats injected with IgG from patients with GAD-Ab and stiff-person syndrome or cerebellar ataxia, NO levels also significantly increased after NMDA administration (p = 0.02). However, this increase was significantly less important than in controls (group by time interaction: p = 0.021). Injection of IgG extracted from patients with paraneoplastic cerebellar ataxia did not impair the NMDAmediated production of NO as compared to controls (p = 0.18). NO levels were significantly higher in the Hu-Ab, Yo-Ab and CV2/CRMP5-Ab groups as compared to the GAD-Ab group (group by time interaction: p < 0.001). Finally, we explored the production of glutamate in the deep cerebellar nuclei as a complement to a previous study. 6 As expected, infusion of NMDA in the cerebellar nuclei reduced the extracellular concentration of glutamate in control animals ( Figure 5 ; p < 0.001). Glutamate levels were significantly higher in rats injected with IgG from patients with GAD-Ab and neurological syndromes than in control groups (group by time interaction: p < 0.001).
Discussion
Our results provide in vivo evidence with fairly acute studies that IgG purified from patients with GAD-Ab and neurological syndromes can alter cerebellar activity, impair learning and affect spinal cord activity in rodents. These effects were observed in two different experimental protocols with the antibodies altering both electrophysiology and neurochemistry in vivo. First, we assessed the increase in the cortical motor response normally induced by repeated somatosensory stimulation in rodents. 12 We previously demonstrated that the cerebellum plays a key role in the modulation of this response, [8] [9] which involves an increased efficiency of the thalamo-cortical pathway. We also recently showed that the intra-cerebellar administration of tetrodotoxin, a sodium channel blocker, blocks the potentiation in the contralateral motor cortex response. This is considered the first step for learning in the paradigm of sustained peripheral stimulation. 10 In the present study, we observed a similar effect after the intracerebellar injection of IgG from GAD-Ab positive patients with stiff-person syndrome or with cerebellar ataxia. We then tested whether the paraspinal administration of these antibodies could affect spinal cord function. Again, IgG isolated from patients with GAD-Ab and stiff-person syndrome or cerebellar ataxia induced repetitive muscle discharges, abnormal exteroceptive reflexes and increased F/M ratios, suggesting that these antibodies can enhance motoneuronal activity. IgG from GAD-Ab positive individuals and no CNS involvement were ineffective in both models. Recently, Sommer et al. described similar results with IgG from a patient with stiff-person syndrome and anti-amphiphysin antibodies. 16 They showed that the injection of the IgG fraction of the patient's serum in rats resulted in a dose-dependent stiffness with spasms resembling those of human stiff-person syndrome. Taken together, our results and those of Sommer et al. strongly support that the stiff-person syndrome is directly caused by the effect of antibodies on spinal cord neurons, both in anti-amphiphysin and anti-GAD positive cases. However, IgG from GADAb positive patients with stiff-person syndrome and from patients with cerebellar ataxia cause the same types of dysfunction in the cerebellum and in the spinal cord, leaving unexplained why these patients develop typically distinct clinical pictures, although there have been some patients described with both syndromes. [17] [18] [19] A few cases have been reported where, in patients with GAD-Ab, symptoms of stiff-person syndrome may improve with immunotherapy and IgGdepleting strategies, but symptoms of cerebellar dysfunction rarely improve. [19] [20] [21] A possible explanation for this different response to treatment is that the cascade of events induced by antibodies differs in both conditions and the vulnerability of various sites in the CNS to GAD-Ab might differ. GAD-Ab acting upon cerebellar pathways might induce lesions reaching an irreversible stage, leading to neuronal destruction and cerebellar atrophy in a chronic situation. This hypothesis is supported by the recent publication of an autopsy of a patient with both cerebellar ataxia and stiff person syndrome showing only Purkinje cells loss and no abnormalities in the spinal cord. 18 In cell and tissue culture systems, IgG from patients with neurological syndromes and GAD-Ab induce a suppression of GABA release, [6] [7] suggesting that they may change the balance between glutamate and GABA and cause glutamate excitotoxicity. To test this hypothesis in the living animal, we studied by microdialysis the effect of these IgG on glutamate and NO production. Our results demonstrate that GAD-Ab decrease NO production and impair the synaptic regulation of glutamate, resulting in increased concentrations of this neurotransmitter in the deep cerebellar nuclei. NO is an important signaling molecule involved in physiological processes such as brain development, synaptic plasticity, sensory processing, and motor learning. 22 The glutamate/NO pathway is of primary importance in the cerebellum, [23] [24] where NMDA-induced production of NO is clearly involved in synaptic plasticity. [25] [26] [27] [28] Moreover, sustained inhibition of NO production induces apoptosis in differentiated cerebellar granules, while compounds which release NO significantly revert this effect. 29 In brain synapses, NO synthase activation is mainly 8 coupled to NMDA-mediated calcium entry at post-synaptic densities through regulatory protein complexes, and NMDA/NO inhibit the pre-synaptic release of glutamate. Accordingly, NO scavengers, NO blockers and inhibitors of NO synthase activity are known to impair motor behavior. 30 Glutamate release inhibition also prevents excitotoxic neuronal death. 31 We show that IgG from patients with GAD-Ab decrease NMDA-mediated NO production, a mechanism that may affect cerebellar activity and eventually lead to cell death. Our results strongly support the hypothesis that antibodies directly cause stiff-person syndrome and cerebellar ataxia in individuals with GAD-Ab, but it remains to be determined whether the GAD-Ab themselves or other auto-antibodies contained in the purified IgG fraction from these patients are responsible. For example, recently some authors reported that antibodies against GABA-A receptor associated protein were also present in patients with stiff-person syndrome and GAD-Ab. 32 The main arguments against a role of GAD-Ab are the intracellular localization of GAD and the fact that GAD-Ab from patients with diabetes mellitus and no neurological signs had no effect in our experiments. Despite these objections, a direct role of GAD-Ab is by no means excluded. First, recent work demonstrates that IgG can be internalized by neurons, 33 making intracellular antigens accessible in experimental settings like ours. Earlier studies already mentioned the ability of IgG to enter neurons. [34] [35] Second, GAD-Ab from patients with or without CNS involvement recognize different epitopes of the GAD protein. 3, 36 Furthermore, GAD-Ab titers are significantly higher in the sera of patients with CNS involvement, some of whom also have evidence of intrathecal synthesis. 3 Eventually, active immunisation studies with GAD or selective purification of GAD-Ab are required to address the question whether GAD-Ab or other uncharacterized auto-antibodies are responsible for CNS disease. However, production of soluble recombinant GAD is very difficult. It requires large-scale production 37 and the extraction of IgG produced by animals immunized with GAD itself remains still a technical challenge. Similarly, further studies will be necessary to understand why some patients develop cerebellar ataxia and others stiff-person syndrome even though they have an apparently identical serological profile. Gathering samples from these rare disorders is essential for these investigations. . F/M ratios in controls (group 1, 6 rats), in rats receiving saline administration (group 2, 6 rats), in rats receiving IgG from patients with GAD-Ab and stiff-person syndrome or cerebellar ataxia (group 3; IgG from a patient with stiff-person syndrome injected in 3 rats, IgG from a patient with cerebellar ataxia injected in 3 rats), in rats receiving IgG from patients without neurological symptoms (group 4, 3 sera injected in 6 rats). Values obtained in left plantaris muscle 1 hour after lumbar paraspinal administration (10 microL over a period of 10 min). Means (+/-SD) are illustrated. Ratios are expressed in %. *: p < 0.05 Figure 4 . Effects of antibodies on NMDA-induced nitric oxide production in rat cerebellum in vivo. Each bar represents the means (+/-SEM). In addition to a group receiving a control solution, IgG from patients with paraneoplastic cerebellar ataxia (anti-Yo: purified IgG fractions from 1 serum injected in 6 rats, anti-Hu: purified IgG fractions from 1 serum injected in 6 rats, anti-CV2: purified IgG fractions from 1 serum injected in 6 rats) were used as controls. For GAD-Ab, purified IgG fractions from a patient with stiff-person syndrome and from a patient with ataxia were injected in a total of 8 rats (4 rats/each serum). Values are expressed as percentages of basal measurements. *: p < 0.05 as compared to the group receiving a control solution or paraneoplastic antibodies. 
